Not currently recruiting at UCSD
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Summary
- Eligibility
- for people ages 18-99 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Incyte Biosciences International Sàrl
- ID
- NCT05287113
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 162 study participants
- Last Updated